Improving outcomes for people with skin tumours including melanoma

NICE | 2019| 2019 surveillance of melanoma: assessment and management (NICE guideline NG14) and improving outcomes for people with skin tumours including melanoma (NICE guideline CSG8)

NICE will update the following guidelines:

Full details are available from NICE 

[NICE Technology appraisal guidance] Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

NICE |  May 2019| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Technology appraisal guidance [TA579]

NICE have publsihed technology appraisal guidance: Evidence-based recommendations on abemaciclib (Verzenios) for hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy.

Full details from NICE 

[NICE Guideline] Prostate cancer: diagnosis and management [NG131]

NICE |  May 2019 | Prostate cancer: diagnosis and management NICE guideline [NG131]

This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

Full details from NICE 

Improving the care of head and neck cancer patients with collaborative dietetics and speech and language therapy intervention

NICE | April  2019 | Improving the care of head and neck cancer patients with collaborative dietetics and speech and language therapy intervention

NICE’s shared learning database highlights the work and benefits to patients of  a project at the University Hospital Birmingham NHSFT; where patients are being seen by Speech and Language Therapists and Dietitians whilst they have radiotherapy (plus or minus chemotherapy) to minimise the morbidity associated with oncology treatments to the head and neck.

The paper describes the individual and operational benefits of this clinical intervention, including reduced weight loss, and admissions to hospital as well as a shortened length of stay for patients who were admitted.   

Improving the care of head and neck cancer patients with collaborative dietetics and speech and language therapy intervention

[NICE Technology Appraisal Guidance] Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

NICE | April 2019 | Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Technology appraisal guidance [TA578]

Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

More evidence on durvalumab is being collected, until September 2021. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Full details from NICE